Endologix, Inc. is a medical device company that specializes in developing, manufacturing, marketing, and selling innovative solutions for the treatment of abdominal aortic aneurysms (AAA) both in the United States and internationally. The company offers a range of minimally invasive endovascular aneurysm repair (EVAR) products, including the AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation abdominal stent graft system. Additionally, Endologix provides an endovascular aneurysm sealing (EVAS) system designed to seal aneurysms while maintaining blood flow to the legs. Their product offerings also include various extensions and accessories to tailor treatments to individual patient anatomies. Founded in 1992 and headquartered in Irvine, California, Endologix has a direct sales force as well as a network of third-party distributors and agents to market its products. The company was previously known as Radiance Medical Systems, Inc. until its name change in May 2002.
PQ Bypass, Inc. is a medical device company based in Milpitas, California, that specializes in developing innovative solutions for the treatment of peripheral vascular disease through minimally invasive procedures. Founded in 2009, the company focuses on addressing long-segment femoropopliteal disease with its advanced products, including the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System. PQ Bypass aims to transform the treatment landscape for peripheral artery disease by providing effective endovascular solutions. The executive team brings extensive experience from leading firms in the medical device sector, enhancing the company's ability to innovate and deliver impactful medical technologies.
TriVascular
Acquisition in 2015
TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma Wine Country. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature.
Nellix
Acquisition in 2010
Nellix has developed an original device designed to address and expand the indication for the less invasive treatment of Abdominal Aortic Aneurysms (AAAs) and Thoratic Aortic Aneurysms (TAAs). Enabling the treatment of all aneurysms with a low profiles delivery system and innovative endograft, the Nellix device has the potential to double the market size for Endovascular Aneurysms Repair (EVAR), which exceeded $800M in 2008 with a 16% CAGR (Med Tech Insight).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.